Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners’ Top …

We recently compiled a list of the Top 10 Holdings of Caligan Partners. In this article, we are going to take a look at where Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) stands against …

70%
OFF

Top 10 Holdings Of Caligan Partners - Insider Monkey

2 weeks from now

Aug 8, 2024 · Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is already up by over 70% for the year as it tries to bounce back from imploding the past two years. The cancer treatment drug …

insidermonkey.com

3%
OFF

Caligan Partners LP Has $15.72 Million Stake In Y-mAbs …

2 weeks from now

Dec 1, 2024 · Caligan Partners LP boosted its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 105.3% during the third quarter, according to its most …

marketbeat.com

3%
OFF

Caligan Partners LP Raises Stake In Y-mAbs Therapeutics, Inc.

2 weeks from now

Dec 1, 2024 · Caligan Partners LP boosted its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 105.3% in the 3rd quarter, according to the company in its …

techdows.com

3%
OFF

Y-mAbs Therapeutics Announces Strategic Business Realignment …

2 weeks from now

5 days ago · CALIGAN PARTNERS LP added 613,175 shares (+105.3%) ... -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage …

nasdaq.com

$7150259
OFF

Y-Mabs Therapeutics Inc. (YMAB) - Insider Monkey

2 weeks from now

Aug 27, 2024 · Caligan Partners Lp. 1,048,425: $7,150,259: ... Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript November 8, 2024Y-mAbs Therapeutics, …

insidermonkey.com

$20.40
OFF

YMAB - Y-mAbs Therapeutics, Inc. (NasdaqGS) - Share Price And …

2 weeks from now

The average one-year price target for Y-mAbs Therapeutics, Inc. is $20.40. The forecasts range from a low of $11.11 to a high of $27.30. ... Top Investors. Y-mAbs Therapeutics, Inc. (YMAB) …

fintel.io

FAQs about Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners’ Top … Coupon?

What is Y-mAbs Therapeutics?

Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Y-mAbs Therapeutics has only been the subject of 2 research reports in the past 90 days. ...

How much did y-mAbs Therapeutics (ymab) earn in a quarter?

In the last reported quarter, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) earned $20.30 million and reported earnings per share of $0.15, surpassing analysts' consensus estimates of $15.55 million and $0.31 respectively. ...

How much does y-mAbs Therapeutics (ymab) earn?

Y-mAbs Therapeutics (NASDAQ:YMAB) has a recorded net income of -$21.43 million. YMAB has generated -$0.49 earnings per share over the last four quarters. What is Y-mAbs Therapeutics's EPS forecast for next year? Y-mAbs Therapeutics's earnings are expected to grow from ($0.57) per share to ($0.38) per share in the next year. ...

Who is y-mAbs Therapeutics?

Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY. Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more. Selling, General and Administrative Excl. Other ...

How can I contact Y-mAbs Therapeutics?

To contact Y-mAbs Therapeutics, you can use their mailing address at 230 Park Avenue Suite 3350, NEW YORK NY, 10169. Alternatively, you can reach out to them via phone at (646) 885-8505 or via email at [email protected]. ...

Should you buy y-mAbs Therapeutics (ymab – research report)?

Truist Financial analyst Nicole Germino maintained a Buy rating on Y-Mabs Therapeutics (YMAB – Research Report) today. The company’s shares closed last Friday at $6.89. According to TipRanks, Germino is a 5-star analyst with an average return of 36.6% and a 41.03% success rate. ...